Join to View Full Profile
1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-930-5446
Dr. Salhotra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Amandeep Salhotra is an oncologist in Duarte, CA and is affiliated with City of Hope's Helford Clinical Research Hospital. He received his medical degree from Maulana Azad Medical College and has been in practice 18 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
University of Virginia Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2012
St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2010- St Elizabeth's Medical CenterResidency, Internal Medicine, 2006 - 2009
Maulana Azad Medical CollegeClass of 1999
Certifications & Licensure
CA State Medical License 2012 - 2026
VA State Medical License 2010 - 2012
MA State Medical License 2009 - 2011
Clinical Trials
- Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation Start of enrollment: 2019 Jul 11
- Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Start of enrollment: 2020 May 12
- Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience.Badri Modi, Dat Ngo, Jason Chen, Dongyun Yang, Haoyue Shan
Bone Marrow Transplantation. 2025-04-01 - Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect.Paul B Koller, Tamer Othman, Dongyun Yang, Sally Mokhtari, Yazeed Samara
Bone Marrow Transplantation. 2025-02-27 - Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.Athalia Rachel Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha
Blood Advances. 2025-02-10
Abstracts/Posters
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023
Press Mentions
Plerixafor Doesn’t Overcome HPC Failure in R-hyperCVAD for Mantle Cell LymphomaSeptember 10th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
